Royalty Pharma reports second quarter 2026 results
Royalty Pharma reported Q2 2026 Portfolio Receipts of $773 million, up 6% year-over-year, driven by 14% growth in core Royalty Receipts to $768 million. The company raised full-year 2026 guidance to $3.40 billion to $3.50 billion, citing strong performance from products like Tremfya, Voranigo and Imdelltra.
Key figures
- Revenue
- $773 million
- Guidance
- Portfolio Receipts $3,400 million to $3,500 million (previously $3,325 million to $3,450 million)
- Revenue Yoy
- 6%
- Adjusted ebitda
- $736 million
- Royalty receipts
- $768 million
- Dividend per share
- $0.235
- Portfolio receipts
- $773 million
- Portfolio cash flow
- $736 million
- Royalty receipts yoy
- 14%
- Share repurchases q2
- $45 million
- Capital deployment ytd
- $1.1 billion
- Net cash from operations
- $728 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.